Parallel Advisors
ARTV icon

Parallel Advisors’s Artiva Biotherapeutics ARTV Stock Holding History

Parallel Advisors’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$520 Buy
+73
New +$737 ﹤0.01% 3896

Other funds holding ARTV

Revelation Capital Management
Revelation Capital Management Sausalito, California $8.01M AUM 49.3% 1-Year Est. Return
Simplify Asset Management
Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Bailard
Bailard Foster City, California $4.94B AUM 25.15% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
State of Wyoming
State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Parallel Advisors's ARTV Position: Q3 2026 in Review

Parallel Advisors opened a new position in Artiva Biotherapeutics (ARTV) in Q3 2026: 73 shares worth $520. The stake represents ﹤0.01% of the portfolio and ranks #3896 among its holdings.

19 funds tracked by Wall St. Rank hold ARTV as of Q3 2026.

  • Parallel Advisors held 73 shares of Artiva Biotherapeutics worth $520 as of Q3 2026.
  • Artiva Biotherapeutics was a new Parallel Advisors position in Q3 2026.
  • Artiva Biotherapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q3 2026, its #3896 holding.
  • 19 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q3 2026.

Based on Parallel Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.